Three-Day Icatibant on Top of Standard Care in Patients With Coronavirus Disease 2019 Pneumonia: A Randomized, Open-Label, Phase 2, Proof-of-Concept Trial.
Saved in:
| Title: | Three-Day Icatibant on Top of Standard Care in Patients With Coronavirus Disease 2019 Pneumonia: A Randomized, Open-Label, Phase 2, Proof-of-Concept Trial. |
|---|---|
| Authors: | Malchair P; Emergency Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain., Giol J; Emergency Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain., García V; Emergency Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain., Rodríguez O; Emergency Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain., Ruibal JC; Emergency Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain., Zarauza A; Emergency Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain., Llopis F; Emergency Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain., Matellán L; Emergency Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain., Bernal T; Emergency Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain., Solís B; Emergency Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain., Otero A; Emergency Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.; Clinical Research Support Unit, Bellvitge Biomedical Research Institute (IDIBELL), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain., Carnaval T; Clinical Research Support Unit, Bellvitge Biomedical Research Institute (IDIBELL), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.; Pharmacology Unit, Department of Pathology and Experimental Therapeutics, School of Medicine and Health Sciences, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain., Jofre H; Radiology Department, Bellvitge Biomedical Research Institute (IDIBELL), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain., Jacob J; Emergency Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain., Solanich X; Internal Medicine Department, Bellvitge Biomedical Research Institute (IDIBELL), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain., Antolí A; Internal Medicine Department, Bellvitge Biomedical Research Institute (IDIBELL), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain., Rocamora G; Internal Medicine Department, Bellvitge Biomedical Research Institute (IDIBELL), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain., Videla S; Clinical Research Support Unit, Bellvitge Biomedical Research Institute (IDIBELL), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.; Pharmacology Unit, Department of Pathology and Experimental Therapeutics, School of Medicine and Health Sciences, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain. |
| Source: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2023 May 24; Vol. 76 (10), pp. 1784-1792. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1537-6591 |
|---|---|
| DOI: | 10.1093/cid/ciac984 |
